216 related articles for article (PubMed ID: 32823831)
1. The Treatment of Opsoclonus-Myoclonus Syndrome Secondary to Neuroblastic Tumours-Single-Centre Experience and Literature Review.
Mizia-Malarz A; Stolpa W; Sobol-Milejska G
Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32823831
[No Abstract] [Full Text] [Related]
2. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.
Wilken B; Baumann M; Bien CG; Hero B; Rostasy K; Hanefeld F
Eur J Paediatr Neurol; 2008 Jan; 12(1):51-5. PubMed ID: 17625938
[TBL] [Abstract][Full Text] [Related]
3. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.
Ertle F; Behnisch W; Al Mulla NA; Bessisso M; Rating D; Mechtersheimer G; Hero B; Kulozik AE
Pediatr Blood Cancer; 2008 Mar; 50(3):683-7. PubMed ID: 17226843
[TBL] [Abstract][Full Text] [Related]
4. Early Detection and Treatment of Neuroblastic Tumor with Opsoclonus-Myoclonus Syndrome Improve Neurological Outcome: A Review of Five Cases at a Single Institution in Japan.
Takama Y; Yoneda A; Nakamura T; Nakaoka T; Higashio A; Santo K; Kuki I; Kawawaki H; Tomiwa K; Hara J
Eur J Pediatr Surg; 2016 Feb; 26(1):54-9. PubMed ID: 26409265
[TBL] [Abstract][Full Text] [Related]
5. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.
Rostásy K; Wilken B; Baumann M; Müller-Deile K; Bieber I; Gärtner J; Möller P; Angelini P; Hero B
Neuropediatrics; 2006 Oct; 37(5):291-5. PubMed ID: 17236108
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED
Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
[TBL] [Abstract][Full Text] [Related]
7. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children.
Pranzatelli MR; Tate ED; McGee NR
Pediatr Blood Cancer; 2018 Aug; 65(8):e27097. PubMed ID: 29727049
[TBL] [Abstract][Full Text] [Related]
8. Opsoclonus-myoclonus Syndrome with Neuroblastoma in Children and their Anaesthetic Management.
Gupta A; Kundal R; Pandey M
J Coll Physicians Surg Pak; 2022 Aug; 32(8):1086-1088. PubMed ID: 35932142
[TBL] [Abstract][Full Text] [Related]
9. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment.
Blaes F; Dharmalingam B
Expert Rev Neurother; 2016 Jun; 16(6):641-8. PubMed ID: 27095464
[TBL] [Abstract][Full Text] [Related]
10. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Ding X; Yang W; Ren Q; Hu J; Yang S; Han W; Wang J; Wang X; Wang H
J Neuroinflammation; 2020 Jun; 17(1):190. PubMed ID: 32546235
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
Burke MJ; Cohn SL
Pediatr Blood Cancer; 2008 Mar; 50(3):679-80. PubMed ID: 16900484
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of neuroblastic tumors with opsoclonus-myoclonus-ataxia syndrome: Follicular structure predicts a better neurological outcome.
Fukushima H; Inoue T; Takama Y; Ishii N; Okuno T; Kobayashi Y; Yoneda A; Nakamura T; Kuki I; Hara J
Pathol Int; 2017 Oct; 67(10):503-509. PubMed ID: 28971571
[TBL] [Abstract][Full Text] [Related]
13. Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma.
Ketterl TG; Messinger YH; Niess DR; Gilles E; Engel WK; Perkins JL
Pediatr Blood Cancer; 2013 Dec; 60(12):E163-5. PubMed ID: 23813921
[TBL] [Abstract][Full Text] [Related]
14. Monocentric retrospective clinical outcome in a group of 13 patients with opsoclonus myoclonus syndrome, proposal of diagnostic algorithm and review of the literature.
Urtiaga Valle S; Souvannanorath S; Leboucq N; Haouy S; Rivier F; Roubertie A; Meyer P
Eur J Paediatr Neurol; 2022 Sep; 40():18-27. PubMed ID: 35926472
[TBL] [Abstract][Full Text] [Related]
15. [Comprehensive treatment of neuroblastoma in children associated with opsoclonus-myoclonus-ataxia syndrome].
Zhao W; Sun Q; Xie Y; Hua Y; Xiong H; Jia J; Lu X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):540-3. PubMed ID: 25224062
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.
Pranzatelli MR; Allison TJ; Tate ED
Eur J Paediatr Neurol; 2018 Jul; 22(4):586-594. PubMed ID: 29555260
[TBL] [Abstract][Full Text] [Related]
17. Another promising treatment option for neuroblastoma-associated opsoclonus-myoclonus syndrome by oral high-dose dexamethasone pulse: lymphocyte markers as disease activity.
Oguma M; Morimoto A; Takada A; Kashii Y; Fukuda T; Mori M; Yamagata T; Sugie H; Momoi MY
Brain Dev; 2012 Mar; 34(3):251-4. PubMed ID: 21531096
[TBL] [Abstract][Full Text] [Related]
18. Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma.
Morales La Madrid A; Rubin CM; Kohrman M; Pytel P; Cohn SL
Pediatr Blood Cancer; 2012 Mar; 58(3):472-4. PubMed ID: 21480475
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Opsoclonus-Myoclonus Syndrome in Patients of the Largest Pediatric Hospital in Latin America.
Zeny MS; do Valle DA; Santos MLSF; Bara TS; Cordeiro ML
Pediatr Neurol; 2024 May; 154():9-14. PubMed ID: 38430891
[TBL] [Abstract][Full Text] [Related]
20. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
